Phase 2 Platform Study in Patients with Advanced Non-Small Lung Cancer who progressed on First-Line Osimertinib Therapy (ORCHARD)

Trial Identifier: D6186C00001
Sponsor: AstraZeneca
Start Date: June 2019
Primary Completion Date: May 2025
Study Completion Date: May 2025
Condition: Lung Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
DK Odense C, DK, 5000
ES A Coruña, ES, 15006
ES Barcelona, ES, 08036
ES Barcelona, ES, 08025
ES Madrid, ES, 28041
ES Madrid, ES, 28046
ES Sevilla, ES, 41009
IT CATANIA, IT, 95123
IT Napoli, IT, 80131
IT Orbassano, IT, 10043
IT Padova, IT, 35128
IT Varese, IT, 21100
JP Chuo-ku, JP, 104-0045
JP Fukuoka-shi, JP, 812-8582
JP Koto-ku, JP, 135-8550
JP Nagoya-shi, JP, 464-8681
JP Osaka-shi, JP, 541-8567
JP Wakayama-shi, JP, 641-8510
KR Seongnam-si, KR, 13620
KR seoul, KR, 06351
KR Seoul, KR, 05505
KR Seoul, KR, 03722
NL Amsterdam, NL, 1081 HV
NL Amsterdam, NL, 1066 CX
NL MAASTRICHT, NL, 6229 HX
NL Nijmegen, NL, 6525 GA
NL Rotterdam, NL, 3015GD
NO Drammen, NO, 3004
NO Oslo, NO, N-0310
NO Trondheim, NO, 7030
SE Stockholm, SE, 17176
US, CA Duarte, CA, US, 91010
US, CA Los Angeles, CA, US, 90048
US, CA Sacramento, CA, US, 95817
US, CA Santa Monica, CA, US, 90404
US, CT New Haven, CT, US, 06510
US, IL Chicago, IL, US, 60612
US, MA Boston, MA, US, 02215
US, MA Boston, MA, US, 02114
US, MD Baltimore, MD, US, 21224
US, MI Grand Rapids, MI, US, 49503
US, NY New York, NY, US, 10017
US, NY New York, NY, US, 10032
US, OR Portland, OR, US, 97239
US, PA Pittsburgh, PA, US, 15232
US, TX Houston, TX, US, 77030
US, WA Seattle, WA, US, 98109